ENVISION
Principal Investigator: Marcel Hungs, MD, PhD
Study Sponsor: Biogen MA Inc. (Biogen)
Location: HealthPartners’s Neuroscience Center, Saint Paul, MN 55130
Purpose of study: Research suggests that a cause of Alzheimer’s disease (AD) may be an abnormal build-up of a protein in the brain called amyloid beta. We are conducting the ENVISION study to confirm if this study drug-Aducanumab- that has been designed to reduce this build-up can help people with Mild Cognitive Impairment (MCI) due to AD or mild AD dementia compared to placebo.
Inclusion Criteria:
– Have Mild Cognitive Impairment due to Alzheimer’s disease or mild Alzheimer’s dementia
– Aged 60-85
Study Requirements:
– Length of study commitment: 130 weeks (2 and ½ years)
– Requirements: you will need to visit a study clinic approximately 40 times so that we can monitor your general health and condition with health assessments such as blood tests, brain MRI scans, neurological examinations, urine tests and vital signs. You will also have up to eight follow-up phone calls.
Study Contact: If you would like to know more about this study, please contact Carrie Weaver at 651-495-6370 or email carrie.a.weaver@healthpartners.com.
Clinical Trials Link (to clinical trials.gov): https://clinicaltrials.gov/stiudy/NCT05310071
Virtual Reality Cognitive Therapy for Alzheimer’s Disease
Principal Investigator: Leah Hanson, PhD
Study sponsor: Clarity Tek
Location: Center for Memory and Aging, Neuroscience Center
Purpose of study:Alzheimer’s disease (AD) and Alzheimer’s disease-related Dementias (ADRD) resulting in cognitive decline affects more than 5.8 million Americans. Given the impact of AD/ADRD on people’s quality of life, there is a great need for therapies focused on cognition. In this study we will test the feasibility, usability, and acceptability of a novel Virtual Reality Cognitive Therapy (VRCT) developed by ClarityTek, Inc. The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled. Participants and their care partners will utilize the VRCT within their home for 30 minutes, 3 times per week, for seven weeks.
Inclusion Criteria:
– Ability to provide and provision of signed and dated informed consent form
– Age 30-89
– Diagnosis of mild cognitive impairment (MCI), probably Alzheimer’s Disease (AD), or Alzheimer’s disease Related Dementias (ADRD)
– Montreal Cognitive Assessment (MoCA) score of 11-25
Exclusion Criteria:
– Non-English speaking
– History of seizure disorder, vertigo disorder, or severe motion sickness
– Severe visual/hearing impairment, aphasia, or facial injury
– Unwilling to participate in all study related activities
– History of any other serious condition that may limit their ability to participate in the intervention, as determined by the investigator
Study Contact:
Clinical Trials office
(651) 495-6363
ClinicalTrials@HealthPartners.com
For more information, please visit the study’s clinicaltrials.gov site at: https://clinicaltrials.gov/study/NCT05788848
